The BENCHMARK Registry (ClinicalTrials.gov Identifier: NCT04579445) is an investigator initiated, observational, multicentre registry that enrolled 2,405 patients from 28 sites across 7 European countries
The Registry 30-day results indicate significant improvements in efficiency without compromising patient safety after implementing the 8 BENCHMARK Practices. The 30-day results demonstrate a reduction in mean length of hospital stay of 2 days after implementation of BENCHMARK Practices, along with a reduction in intensive care usage (combined ICU/CCU/IMC time) of 14 hours. Patient safety was uncompromised, with no change in all-cause mortality, rehospitalisation or incidence of stroke, and both patient and staff satisfaction were increased following implementation of the BENCHMARK Practices.1
A recent analysis presented at the PCR London Valves 2023 conference compared outcomes from BENCHMARK Registry centres across 5 European countries (France, Spain, Germany, Italy and Austria). The results demonstrate that implementing BENCHMARK Practices improves efficiency without compromising patient safety across different European countries, despite differences in healthcare systems and patient populations.2
The BENCHMARK Data Comparison Tool is designed to offer an opportunity to the European hospitals that are currently implementing TAVI optimisation practices to compare their aggregated outcomes such as length of stay, ICU/CCU/IMC usage with that of BENCHMARK Registry European results. Besides, this tool also enables such comparison with the results from sub-analysis of France, Spain, Germany, Italy and Austria.
The self-reported aggregated data entered by hospitals will be used to generate a report comparing the selected parameters published in the BENCHMARK Registry. Hospitals may benefit from such a report which could potentially highlight areas of further progress in standardizing the pre-peri-post TAVI procedural practices around Europe.
Edwards Benchmark Program is an evidence-based global TAVI patient pathway optimisation program, developed for all stages of the clinical pathway. The program started in 2018 and is based on the principles of North American 3M TAVR and European FAST TAVI studies. Data from the BENCHMARK Registry further validated the program and its reproducibility in varied healthcare systems. To know more about and to join the Edwards Benchmark program in Europe, contact Benchmark_EU@edwards.com.
References:
1. Frank D. et al. A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study. Eur Heart J. 2024 Mar 30:ehae147. doi: 10.1093/eurheartj/ehae147. PMID: 38554125
2. Saia F. et al. PCR London Valves 19–21 November 2023, London, UK